Tom Seijkens

Since 2022, I have been working as an internist-oncologist at the Netherlands Cancer Institute. My areas of interest are immunotherapy and cell therapy, including treatments with tumor infiltrating lymphocytes (TIL), T cell receptor (TCR) modified T cells and chimeric antigen receptor (CAR) T cells. These innovative treatments are frequently used at the NKI. Partly thanks to the good cooperation within the Centre for Cell Therapy of the NKI, more and more people with metastatic cancer can be treated with these innovative therapies.